Webinar archive: Genome editing, CRISPR, and what comes next
Source: Webinar archive: Genome editing, CRISPR, and what comes next
S
TAT senior science writer Sharon Begley and national biotech columnist Adam Feuerstein tell us what CRISPR is (and is not), what other genome-editing methods are already being tested, and which companies are betting on these technologies to one day treat, cure, or prevent disease.
This is the year when CRISPR will move out of the lab and into patients in the first U.S. clinical trials of the genome-editing technology. See what Sharon, Adam, and webinar participants think success might look like.
Published at Thu, 22 Feb 2018 20:46:21 +0000
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.